Home › NCT05509933

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* • Patients 18-80 years of age with a diagnosis of a hematological malignancy

  * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies

Exclusion Criteria:

* • Patients enrolled in investigational clinical trials

  * Sct for non hematologic malignancies

About the study

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

What is being tested

• Budesonide (drug)

Sponsor: Henry Ford Health System · Participants: 110 · Started: Nov 9, 2022

Contact the study team

• shatha farhan · Phone: 3137133910

Official record on ClinicalTrials.gov — NCT05509933

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.